A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
ALX Oncology Inc.
NiKang Therapeutics, Inc.
Pliant Therapeutics, Inc.
Eli Lilly and Company
MOMA Therapeutics
Eli Lilly and Company
Kivu Bioscience Inc.
MOMA Therapeutics
Astellas Pharma Inc
Kestrel Therapeutics, Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
National Cancer Institute (NCI)
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Plexium, Inc.
Revolution Medicines, Inc.
USWM, LLC (dba US WorldMeds)
Coherus Oncology, Inc.
Conjupro Biotherapeutics, Inc.
Alterome Therapeutics, Inc.
IDEAYA Biosciences
Aptamer Sciences, Inc.
Erasca, Inc.
Novartis
National Cancer Institute (NCI)
GlaxoSmithKline
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Institut Paoli-Calmettes
Orano Med LLC
Tomsk National Research Medical Center of the Russian Academy of Sciences
Imugene Limited
I-Mab Biopharma US Limited
University of California, Davis
ViroMissile, Inc.
Pfizer
Pfizer
Tizona Therapeutics, Inc
Genentech, Inc.
Angiex, Inc.
MacroGenics
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Prelude Therapeutics
General Oncology, Inc.
Kyowa Kirin Co., Ltd.
Zhejiang University